LEE'S PHARM

A research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China.

Pharmaceutical Products

Various products stemming from both internal R&D efforts and collaborations with partnerships

Research & Development

Clinical Trials

COVID-19 testing

Pharmacovigilance

Medical Frontiers

Manufacturing Sites

Self-owned manufacturing sites in Hefei, Anhui and Nansha, Guangzhou, China.

Investor Relations

Latest financial reports, announcements, stock information and investor contacts

News & Media

RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Seoul, Korea, San Francisco, Ca., Hong Kong, China —Sept. 4, 2018 -- SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapyproducts for cancer……

SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

YONGIN, South Korea, 14 February 2018 – GC Pharma (formerly known as Green CrossCorporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee'sPharmaceutical (HK) Limited……

RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Seoul, Korea, San Francisco, Ca., Hong Kong, China —Sept. 4, 2018 -- SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapyproducts for cancer……

SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

YONGIN, South Korea, 14 February 2018 – GC Pharma (formerly known as Green CrossCorporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee'sPharmaceutical (HK) Limited……

COVID-19 Response

Measures taken by Lee’s Pharm during COVID-19 Pandemic

Careers at Lee’s Pharm.

We strive continually to attract and retain talented professionals who share our values.